These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7533452)

  • 21. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up.
    Fabricius PG; Hannaford JM
    Br J Urol; 1992 Nov; 70 Suppl 1():10-6. PubMed ID: 1281726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Dunzendorfer U
    Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
    Woods AL
    Mil Med; 1992 Jul; 157(7):361-4. PubMed ID: 1382248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
    Guthrie R
    J Fam Pract; 1994 Aug; 39(2):129-33. PubMed ID: 7520053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience: symptomatic management of BPH with terazosin.
    Dunzendorfer U
    Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of terazosin in patients with benign prostatic hyperplasia.
    Matzkin H; Soloway MS; Rangel MC; Laddu A
    Eur Urol; 1992; 21(2):126-30. PubMed ID: 1379921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    Lee E; Lee C
    Br J Urol; 1997 Oct; 80(4):606-11. PubMed ID: 9352700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
    Hillman AL; Schwartz JS; Willian MK; Peskin E; Roehrborn CG; Oesterling JE; Mason MF; Maurath CJ; Deverka PA; Padley RJ
    Urology; 1996 Feb; 47(2):169-78. PubMed ID: 8607228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
    Lowe FC
    Urology; 1994 Jul; 44(1):46-51. PubMed ID: 7518981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
    Fabricius PG; Weizert P; Dunzendorfer U; Hannaford JM; Maurath C
    Prostate Suppl; 1990; 3():85-93. PubMed ID: 1689173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
    Lloyd SN; Buckley JF; Chilton CP; Ibrahim I; Kaisary AV; Kirk D
    Br J Urol; 1992 Nov; 70 Suppl 1():17-21. PubMed ID: 1281727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
    Dogra PN; Biswas NR; Ravi AK; Mani K; Kumar V
    J Indian Med Assoc; 2005 Feb; 103(2):108-10, 112. PubMed ID: 16008322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ; Howe W; MacDonald R
    BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
    Kirby RS
    Br J Urol; 1998 Sep; 82(3):373-9. PubMed ID: 9772873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
    Djavan B; Roehrborn CG; Shariat S; Ghawidel K; Marberger M
    J Urol; 1999 Jan; 161(1):139-43. PubMed ID: 10037386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.